Anti-CD20 Dosing for Relapse Prevention in Multiple Sclerosis
For ocrelizumab in relapsing MS, the standard regimen is an initial course of 300 mg × 2 (two weeks apart), followed by 600 mg every 6 months indefinitely to maintain full relapse prevention. 1
Standard Dosing Protocol
The FDA-approved dosing schedule for ocrelizumab consists of:
- Initial treatment: Two 300 mg IV infusions administered 2 weeks apart
- Maintenance: 600 mg IV infusion every 24 weeks (6 months) thereafter
This regimen was established in the pivotal RMS trials (Studies 1 and 2) that demonstrated significant reduction in annualized relapse rate compared to interferon beta-1a over 96 weeks. 1
Duration of Treatment
Continuous therapy is the current standard, as the clinical trials establishing efficacy used ongoing treatment without planned discontinuation. The FDA label does not specify a finite treatment duration—patients continue therapy indefinitely as long as they tolerate it and benefit from it. 1
Emerging Evidence on Finite Dosing
Recent research challenges the necessity of indefinite treatment:
- A 2025 prospective study found that only 2 standard courses of ocrelizumab (initial 300 mg × 2 plus one 600 mg dose 6 months later) maintained clinical and radiological remission in 68% of patients for up to 46 months. 2
- However, this finite-course approach showed significantly shorter time to disease reactivation compared to continuous dosing (40.5 vs 46 months; difference -5.5 months, p=0.011). 2
- Importantly, peripheral B-cell repopulation did not predict reactivation, suggesting disease control mechanisms extend beyond simple B-cell depletion. 2
Alternative Dosing Strategies
Extended-interval dosing (EID) and dose reduction have been explored as de-escalation strategies:
- A 2024 observational study showed that reducing ocrelizumab from 600 mg to 300 mg every 6 months after 2 years of standard dosing maintained efficacy with no relapses or new MRI activity over mean 17-month follow-up. 3
- A 2025 meta-analysis found EID showed no significant difference in relapse rates (RR=0.67), MRI activity (RR=0.87), disability progression (RR=0.96), or NEDA-3 status (RR=1.12) compared to standard dosing. 4
Clinical Algorithm for Dosing Decisions
For newly diagnosed patients:
- Start with standard FDA-approved regimen (300 mg × 2, then 600 mg q6 months)
- Continue for minimum 2 years to establish disease control
- Assess for dose modification only after documented stability
After 2+ years of stability (no relapses, no new MRI lesions, stable disability):
- Consider dose reduction to 300 mg q6 months if infection risk is elevated or hypogammaglobulinemia develops 3
- Consider extended-interval dosing (q7-9 months) as alternative 4
- Monitor closely with MRI every 6 months during first year of modification
Critical caveats:
- Finite-course therapy (stopping after 2 doses) carries 32% reactivation risk and should only be considered in exceptional circumstances requiring treatment cessation 2
- The standard continuous regimen remains the evidence-based approach for optimal relapse prevention
- Alternative dosing strategies are investigational and not FDA-approved, though emerging data suggest they may be reasonable in select stable patients